BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

BioNTech and Regeneron will face off against Merck and Moderna, which are advancing their investigational cancer vaccine mRNA-4157/V940 in combination with Keytruda, in advanced melanoma.